Rheumatoid lung disease

Global Rheumatoid Arthritis Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, Other Health, Medical specialties, Clinical medicine, Medicine, Rheumatology, Arthritis, Connective tissue diseases, Autoimmune diseases, Rheumatoid arthritis, Arthritis Australia, Rheumatoid lung disease

b'The "Global Rheumatoid Arthritis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2021, provides Rheumatoid Arthritis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Rheumatoid Arthritis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2021, provides Rheumatoid Arthritis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Rheumatoid Arthritis patients, history of the disease at the population level (Rheumatoid Arthritis prevalence, Rheumatoid Arthritis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Rheumatoid Arthritis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Rheumatoid Arthritis market sizing, assessing market potential, and developing drug forecast models\nIdentify Rheumatoid Arthritis patients segments through age groups, gender, and disease sub-types\nEvaluate Rheumatoid Arthritis market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005184/en/\n'

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Retrieved on: 
Thursday, April 1, 2021
Lung disorders, Respiratory diseases, Lung, Anatomy, United Therapeutics, Interstitial lung disease, Pulmonary hypertension, Rheumatoid lung disease, Idiopathic pulmonary fibrosis

Interstitial lung disease (ILD) is a group of lung diseases in which marked scarring occurs within the lungs.

Key Points: 
  • Interstitial lung disease (ILD) is a group of lung diseases in which marked scarring occurs within the lungs.
  • It is often complicated by pulmonary hypertension (PH; high blood pressure in the lungs), which further symptoms and decreases survival.
  • "The FDA approval of Tyvaso for patients with PH-ILD is a landmark treatment advancement for this vulnerable patient population," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease

Retrieved on: 
Wednesday, January 13, 2021
United Therapeutics, Anatomy, Orphan drugs, Organ systems, Interstitial lung disease, Pulmonary hypertension, Treprostinil, Rheumatoid lung disease, Pulmonary fibrosis

and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the New England Journal of Medicine.

Key Points: 
  • and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ --United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the New England Journal of Medicine.
  • Interstitial lung disease (ILD) is a group of lung diseases in which marked scarring occurs within the lungs.
  • "Patients with both interstitial lung disease and pulmonary hypertension are more likely to have a worse course of disease and worse survival rate than patients with interstitial lung disease alone.
  • United Therapeutics submitted a supplemental New Drug Application (sNDA) for Tyvaso for the treatment of PH-ILD based on the results of the INCREASE study.

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Retrieved on: 
Friday, February 28, 2020
FDA, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Interstitial lung disease, Pulmonary fibrosis, Respiratory disease, ILD, Medical specialties, RTT, Rheumatoid lung disease, Medicine, Idiopathic pulmonary fibrosis, Pneumonia

Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan and Brazil.

Key Points: 
  • Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan and Brazil.
  • When SSc affects the lungs, it can cause interstitial lung disease (ILD), known as SSc-ILD.2,6 ILD is the leading cause of mortality in SSc, accounting for almost 35% of SSc-related deaths.7
    SSc-ILD is a life-changing disease.
  • Striving to improve the lives of people living with pulmonary fibrosis, we are pleased with the Committees positive opinion, which represents an important step forward in helping to slow down the progression of this rare and life-changing disease.
  • Patients remained on the study treatment for at least 52 weeks of treatment or for a maximum of 100 weeks of treatment.

Biodesix Highlights Clinical Data Demonstrating the Potential of EarlyCDT Lung Blood Test to Improve Early Detection of Lung Cancer

Retrieved on: 
Monday, September 9, 2019
Biotechnology, Health, Clinical trials, Oncology, Medicine, Clinical medicine, Health, Lung nodule, Lung cancer screening, Lung cancer, Cancer screening, Cancer, Screening, High-resolution computed tomography, Rheumatoid lung disease

In June, Biodesix announced acquisition of Oncimmune and the EarlyCDT Lung test in the United States .

Key Points: 
  • In June, Biodesix announced acquisition of Oncimmune and the EarlyCDT Lung test in the United States .
  • We look forward to continuing our work with Oncimmune to extend the utility of the EarlyCDT Lung test in the U.S. to include lung cancer screening.
  • In addition to its potential in lung cancer screening, the EarlyCDT Lung test also helps physicians to determine if a pulmonary nodule is potentially cancerous, helping physicians manage nodule patients.
  • Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer.

Rheumatoid Arthritis Market and Forecast Analysis to 2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 20, 2019
Health, Pharmaceutical, Medical specialties, Medicine, RTT, Clinical medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Rheumatoid arthritis, Arthritis, Rheumatoid lung disease, Adalimumab

The "Rheumatoid Arthritis Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rheumatoid Arthritis Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to progressive joint deformity, disability, and occasionally premature death.
  • US price increases and rising disease prevalence will lead to net growth of the market, despite biosimilar erosion.
  • Prevalent cases of RA will increase slightly in the US, Japan, and five major EU markets over the next 20 years.